Author: Ravi Shankar

CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, announced today a net loss of $13.5 million, or ($2.23) per diluted share, on net sales of $34.5 million for the fourth quarter of fiscal year 2026 compared to a net loss of $7.2 million, or ($1.20) per diluted share, in the fourth quarter of the prior fiscal year. Our net loss for the fourth quarter of fiscal 2026 includes a non-recurring non-cash charge of $10.4 million related to the impairment of our Carlsbad, CA manufacturing facility due to its underutilization. Excluding this charge, our net loss for the fourth quarter of fiscal 2026 would have been $3.1 million, or ($0.52) per diluted share.

Net sales during the three months ended June 30, 2026, increased $0.6 million, or 1.9%, to $34.5 million compared to $33.9 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 0.6% to $31.9 million. Private-label contract manufacturing sales increased primarily due to increased orders from one of our larger customers, partially offset by reduced orders from other existing customers.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 22% to $2.6 million during the fourth quarter of fiscal year 2026, as compared to $2.1 million for the fourth quarter of fiscal year 2025. The increase in CarnoSyn® beta-alanine royalty, licensing, and raw material sales revenue during the fourth quarter of fiscal 2026 was primarily due to increased raw material sales to existing customers and increased royalty income.

Our net loss for our fiscal year ending June 30, 2026, was $20.7 million, or ($3.43) per diluted share, compared to a net loss of $13.6 million, or ($2.28) per diluted share for fiscal year 2025. Our net loss for fiscal 2026 included the non-recurring, non-cash charge of $10.4 million related to the impairment of our Carlsbad, CA. manufacturing facility, and related assets. Excluding this charge, our net loss for fiscal 2026 would have been $10.3 million or ($1.71) per diluted share.

Net sales during the year ended June 30, 2026, increased $12.7 million, or 10%, to $142.5 million as compared to $129.9 million recorded in the comparable prior year period. During the year ended June 30, 2026, private-label contract manufacturing sales increased 11% to $134.6 million, as compared to $121.8 million in the comparable prior period. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 2% to $7.9 million during fiscal 2026, as compared to $8.1 million for fiscal 2025.

While we grew sales during the three and twelve months ended June 30, 2026, we experienced a net loss primarily due to underutilization of our available factory capacities and a non-cash impairment charge against our Carlsbad, CA manufacturing facility. 

To increase our capacity utilization and reduce operating costs, we have initiated the consolidation of our USA manufacturing operations into our Vista, CA facility, which includes the anticipated sale of our Carlsbad, CA manufacturing facility. We have also initiated a comprehensive review process to explore strategic alternatives focused on maximizing shareholder value including evaluating a full range of strategic growth paths, potential mergers, acquisitions, joint ventures, or a sale of the Company.

As of June 30, 2026, we had cash of $7.5 million and working capital of $27.7 million, compared to $12.3 million and $30.5 million respectively, as of June 30, 2025. As of June 30, 2026, we had $17.7 million of borrowing capacity on our credit facility of which we had outstanding borrowings of $7.7 million.

Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, “We are taking decisive steps to strengthen our financial position and better align our operations with current market demand. The planned sales of our Carlsbad, CA Headquarters building and the expected sale of the Carlsbad, CA manufacturing facility are an important part of this effort and are expected to provide additional liquidity, reduce debt, and eliminate significant excess manufacturing capacity. We believe we can successfully consolidate production into our Vista, CA facility without disrupting our customers, while continuing to focus on growing revenue, expanding customer relationships and reducing costs.”

An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/).

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging, and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please see our website at http://www.nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, our future revenue, profits, and financial condition. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

SOURCE – Natural Alternatives International, Inc.

CONTACT – Kenneth Wolf, President, Chief Operating Officer and Acting Principal Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or investor@nai-online.com.

Web site: http://www.nai-online.com

NATURAL ALTERNATIVES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
	(Unaudited)
	Three Months Ended														Year Ended
	June 30,														June 30,
		2026							2025							2026							2025
NET SALES	$	34,508			100.0	%		$	33,866			100.0	%		$	142,515			100.0	%		$	129,860			100.0	%
Cost of goods sold		32,782			95.0	%			30,331			89.6	%			133,518			93.7	%			120,571			92.8	%
Gross profit		1,726			5.0	%			3,535			10.4	%			8,997			6.3	%			9,289			7.2	%
Other selling, general & administrative expenses		4,460			12.9	%			4,079			12.0	%			17,296			12.1	%			16,549			12.7	%
Settlement of legal proceedings & associated expense		32			0.1	%			1,400			4.1	%			44			0.0	%			1,400			1.1	%
Selling, general & administrative expenses		4,492			13.0	%			5,479			16.2	%			17,340			12.2	%			17,949			13.8	%
Impairment loss		10,409			30.2	%										10,409			7.3	%
LOSS FROM OPERATIONS		(13,175	)		-38.2	%			(1,944	)		-5.7	%			(18,752	)		-13.2	%			(8,660	)		-6.7	%
Other expense, net		(319	)		-0.9	%			(875	)		-2.6	%			(1,513	)		-1.1	%			(2,080	)		-1.6	%
LOSS BEFORE TAXES		(13,494	)		-39.1	%			(2,819	)		-8.3	%			(20,265	)		-14.2	%			(10,740	)		-8.3	%
Income tax expense		46							4,397							430							2,835
NET LOSS	$	(13,540	)					$	(7,216	)					$	(20,695	)					$	(13,575	)
NET LOSS PER COMMON SHARE:
Basic:	$	(2.23	)					$	(1.20	)					$	(3.43	)					$	(2.28	)
Diluted:	$	(2.23	)					$	(1.20	)					$	(3.43	)					$	(2.28	)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		6,071							6,003							6,028							5,947
Diluted		6,071							6,003							6,028							5,947

NATURAL ALTERNATIVES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
	June 30,				June 30,
		2026				2025
ASSETS
Cash and cash equivalents	$	7,388			$	12,325
Restricted cash		86				–
Accounts receivable, net		20,650				14,644
Inventories, net		30,753				24,871
Other current assets		6,557				7,436
Total current assets		65,434				59,276
Property and equipment, net		35,605				50,890
Operating lease right-of-use assets		24,062				41,054
Other noncurrent assets, net		1,345				719
Total Assets	$	126,446			$	151,939
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable and accrued liabilities		26,514				24,483
Line of Credit		7,749				1,900
Mortgage note payable		10,939				8,933
Operating lease liability		31,285				48,197
Total Liabilities		76,487				83,513
Stockholders’ Equity		49,959				68,426
Total Liabilities and Stockholders’ Equity	$	126,446			$	151,939

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman.

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA approval and the launch of Genio in the United States.

Liam Kelly brings more than 25 years of leadership experience. He served as Chairman, President and Chief Executive Officer of Teleflex Incorporated (NYSE: TFX), a global provider of medical technology products, until January 2026. He led Teleflex as President and Chief Executive Officer from January 2018 and as Chairman of the Board from May 2020. Mr. Kelly joined Teleflex in 2009 and held a series of senior operating roles, including President of EMEA, President, International, President, Americas, and Chief Operating Officer. Before Teleflex, he spent ten years at Hill-Rom Holdings, Inc. in senior management roles. Mr. Kelly is a director of Enovis Corporation (NYSE: ENOV) and holds a Bachelor of Business Studies from the University of Limerick.

“Nyxoah is entering a new chapter, with the United States at the center of our growth strategy. We are very pleased to welcome Liam as our new CEO. He is a seasoned U.S. MedTech executive with a strong track record of scaling organizations, driving commercial performance and creating shareholder value,” said Robert Taub, Chairman of Nyxoah. “On behalf of the Board, I also want to thank Olivier for his leadership over the past seven years and his contribution in bringing Nyxoah from clinical development through FDA approval and into U.S. commercialization.”

“I am incredibly excited to join Nyxoah at this pivotal stage,” said Liam Kelly. “Genio is a truly differentiated technology in the treatment of sleep apnea. The technology has tremendous potential to impact patient lives globally. The U.S. launch is still in its early stages, and the momentum we’re seeing in physician adoption gives me great confidence in what lies ahead. Drawing on my experience at Teleflex building and scaling global businesses, I look forward to working with the Nyxoah team to scale the business and bring Genio to many more OSA patients.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use.

For more information, please visit http://www.nyxoah.com.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the appointment of the Chief Executive Officer and the related leadership transition; the Company’s leadership and organizational structure; the Company’s commercialization strategy in the U.S. market; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah

Rémi Renard, Head of Investor Relations & Corporate Communication
IR@nyxoah.com

Attachment

• ENGLISH_Nyxoah Appoints Liam Kelly as CEO_FINAL

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — High Income Securities Fund (NYSE: PCF) (the “Fund”) today announced that the Fund’s Board of Trustees (the “Board”) has declared the next three monthly distributions under the Fund’s managed distribution plan.

Under the Fund’s managed distribution plan, the Fund intends to make monthly distributions to common stockholders at an annual rate of 10% (or 0.8333% per month) for 2026, based on the net asset value of $6.96 of the Fund’s common shares as of December 31, 2025.

The next three distributions declared under the managed distribution plan are as follows:

Month	Rate	Record Date	Payable Date
October	$0.0580	October 20, 2026	October 30, 2026
November	$0.0580	November 17, 2026	November 30, 2026
December	$0.0580	December 22, 2026	December 31, 2026

Under the managed distribution plan, to the extent that sufficient investment income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital. To the extent that the Fund’s net investment income and net realized capital gains exceed the aggregate amount distributed pursuant to the managed distribution plan, the Fund may make an additional year-end distribution. No conclusions should be drawn about the Fund’s investment performance from the amount of the distributions. The Board may amend the terms of the managed distribution plan or terminate the plan at any time.

The Fund will issue a notice to stockholders that will provide an estimate of the composition of each distribution. For tax reporting purposes the actual composition of the total amount of distributions for each year will continue to be provided on a Form 1099-DIV issued after the end of the year.

CONTACT: Contact: Ultimus Fund Solutions, BulldogFA@ultimusfundsolutions.com

Award recognizes Navitas’ leadership in ultra-high-voltage (UHV) SiC technology and resilient U.S.-anchored manufacturing supply chain

TORRANCE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation GaNFast^™ gallium nitride (GaN) and GeneSiC^™ silicon carbide (SiC) power semiconductors, today announced it has been awarded the ALATTIS (Accelerated, Large-Area, 10 kV SiC IGBT) program to develop next-generation 10 kV silicon carbide (SiC) power semiconductor technology.

Following a rigorous competitive evaluation, the U.S. Army selected Navitas from among leading U.S. silicon carbide technology companies in recognition of its unmatched leadership in UHV SiC innovation, proven ability to deliver defense-grade performance and reliability, and resilient U.S.-anchored manufacturing ecosystem for advanced power semiconductor technologies.

The ALATTIS prototype project will develop, execute, and validate a novel domestic manufacturing process for ultra-high-voltage (≥10 kV) silicon SiC power semiconductor devices through iterative design, fabrication, and testing.

The project is sponsored by the Army Research Laboratory (ARL), which operates under the U.S. Army Combat Capabilities Development Command (DEVCOM). The ALATTIS prototype program seeks to develop, execute, and validate a novel and currently unavailable domestic manufacturing process for 10 kV IGBTs. ALATTIS is supported by the Joint Experimentation and Technology Accelerator (JETX) with the aim of advancing high-power electronics for critical defense and infrastructure applications. The program will accelerate the development of next-generation 10 kV SiC insulated-gate bipolar transistors (IGBTs) and associated PiN diode technologies for mission-critical systems used by the Armed Forces.

Navitas’ GeneSiC™ SiC power semiconductor portfolio, led by its flagship trench-assisted planar (TAP) MOSFET architecture, spans voltage ratings from 650 V to 6.5 kV and is engineered, manufactured, and supported by a resilient U.S.-anchored supply chain, enabling secure domestic production of advanced power semiconductor technologies for next-generation defense and critical infrastructure applications. Navitas has pioneered multiple industry firsts in UHV SiC, including:

• 6.5 kV SiC thyristors in 2010, recognized with a 2010 R&D 100 Award
• 10–15 kV PiN diodes in 2012
• 6.5 kV SiC MOSFETs commercial release in 2021

“The ALATTIS award marks a significant milestone in advancing ultra-high-voltage silicon carbide (SiC) power devices and recognizes Navitas’ over 20 years of innovation in delivering reliable, ultra-high-voltage, high-power SiC technologies,” said Siddarth Sundaresan, SVP and Chief Technology Officer at Navitas. “This program enables Navitas to extend its leadership beyond SiC MOSFETs by developing next-generation 10 kV SiC IGBTs built on our unique, patented trench-assisted planar (TAP) architecture and integrated with advanced PiN diode technologies.”

To learn more about Navitas’s capabilities in UHV SiC technology, please contact a Navitas Representative or email: info@navitassemi.com.

About Navitas
Navitas Semiconductor (Nasdaq: NVTS) is a next-generation power semiconductor leader in gallium nitride (GaN) and IC integrated devices, and high-voltage silicon carbide (SiC) technology, driving innovation across AI data centers, performance computing, energy and grid infrastructure, and industrial electrification. With more than 30 years of combined expertise in wide-bandgap technologies, GaNFast™ power ICs integrate GaN power, drive, control, sensing, and protection, delivering faster power delivery, higher system density, and greater efficiency. GeneSiC™ high-voltage SiC devices leverage patented ‘trench-assisted planar technology’ to provide industry-leading voltage capability, efficiency, and reliability for medium-voltage grid and infrastructure applications. Navitas has over 300 patents issued or pending and is the world’s first semiconductor company to be CarbonNeutral^®-certified.

Navitas Semiconductor, GaNFast, GaNSense, GeneSiC, and the Navitas logo are trademarks or registered trademarks of Navitas Semiconductor Limited and affiliates. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

About DEVCOM ARL
DEVCOM ARL is the Army’s sole fundamental research laboratory serving as the nexus of science between the military, academia, and industry. Operating under U.S. Army Futures and Concepts Command and the U.S. Army Transformation and Training Command, ARL executes globally recognized research to accelerate delivery of war-winning, disruptive technologies for tomorrow’s Army.
For information, visit the Army Research Laboratory website.

Contact Information
Navitas Semiconductor
Vipin Bothra
info@navitassemi.com

Navitas Investor Contacts
Leanne Sievers | Brett Perry
Shelton Group
sheltonir@sheltongroup.com

Cautionary Statement Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are attempts to predict or indicate future events or trends or similar statements that are not a reflection of historical fact. Forward-looking statements may be identified by the use of words such as “we expect” or “are expected to be,” “estimate,” “plan,” “project,” “forecast,” “intend,” “anticipate,” “believe,” “seek,” or other similar expressions. Forward-looking statements are made based on estimates and forecasts of financial and performance metrics, projections of market opportunity and market share and current indications of customer interest, all of which are based on various assumptions, whether or not identified in this press release. All such statements are based on current expectations of the management of Navitas and are not predictions of actual future performance. Forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions and expectations. Many actual events and circumstances that affect performance are beyond the control of Navitas and, forward-looking statements are subject to a number of uncertainties. Our businesses are subject to certain risks that could materially and adversely affect our respective business, financial condition, results of operations, or the value of our securities. For Navitas, these and other risk factors are discussed in the Risk Factors section of our most recent annual report on Form 10-K, as updated in the Risk Factors section of our most recent quarterly report on Form 10-Q, and in other documents we file with the SEC. If any of these risks, as discussed in more detail in our SEC reports, materialize or if our assumptions underlying forward-looking statements prove to be incorrect, actual results could differ materially from the results implied by these forward-looking statements.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/48bde051-b30b-4423-874c-4e9ff912306a

OSWEGO, N.Y., Sept. 28, 2026 (GLOBE NEWSWIRE) — James A. Dowd, President and CEO of Pathfinder Bancorp, Inc., the bank holding company of Pathfinder Bank (NASDAQ: PBHC) (listing: PathBcp), has announced that the Company has declared a cash dividend of $0.10 per share on the Company’s voting common and non-voting common stock relating to the fiscal quarter ending September 30, 2026. The third quarter 2026 dividend will be payable to all shareholders of record on October 16, 2026 and will be paid on November 6, 2026.

About Pathfinder Bancorp, Inc.
Pathfinder Bank is a New York State chartered commercial bank headquartered in Oswego, whose deposits are insured by the Federal Deposit Insurance Corporation. The Bank is a wholly owned subsidiary of Pathfinder Bancorp, Inc., (NASDAQ SmallCap Market; symbol: PBHC, listing: PathBcp). The Bank has twelve full service offices located in its market areas consisting of Oswego and Onondaga County and one limited purpose office in Oneida County.

This release may contain certain forward-looking statements, which are based on management’s current expectations regarding economic, legislative, and regulatory issues that may impact the Company’s earnings in future periods. Factors that could cause future results to vary materially from current management expectations include, but are not limited to, general economic conditions, changes in interest rates, deposit flows, loan demand, real estate values, and competition; changes in accounting principles, policies, or guidelines; changes in legislation or regulation; and economic, competitive, governmental, regulatory, and technological factors affecting the Company’s operations, pricing, products, and services.

CONTACT: James A. Dowd, President and CEO, (315) 343-0057

TEL AVIV, ISRAEL, Sept. 28, 2026 (GLOBE NEWSWIRE) — Arbe Robotics Ltd. (NASDAQ: ARBE), (TASE: ARBE) (“Arbe” or the “Company”), a global leader in ultra-high-resolution radar solutions, today announced the closing of its previously announced underwritten registered direct offering of 833,334 ordinary shares at a purchase price of $0.60 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 24,166,666 ordinary shares at a purchase price of $0.5999 per share, which equals the offering price per ordinary share less the $0.0001 exercise price per share of each pre-funded warrant. The pre-funded warrants are immediately exercisable and will not expire until exercised in full. All ordinary shares and pre-funded warrants sold in the offering were offered by the Company.

Aggregate gross proceeds to the Company from the offering were approximately $15 million before deducting underwriting discounts and commissions and other offering expenses. Arbe intends to use the net proceeds from this offering for working capital and general corporate purposes, including, but not limited to, scaling its operations to support growing commercial opportunities, including the recently announced selection of Arbe’s radar technology for a Level 3 passenger vehicle program of one of the world’s largest automotive groups and its intended expansion into the defense and counter-drone markets, as well as to potentially pursue strategic merger and acquisition opportunities.

This deal was led by two institutional investors, including AWM Investment Company, Inc., the investment adviser of the Special Situations Funds, which has also participated in many of the Company’s previous financings. Canaccord Genuity acted as sole bookrunner for the offering.

The securities described above were offered pursuant to a registration statement on Form F-3 (File No. 333-287805), originally filed on June 5, 2025, with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on June 13, 2025. The offering was made only by means of a prospectus and a prospectus supplement which forms a part of the effective registration statement relating to the offering. Electronic copies of the final prospectus may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained by contacting Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Arbe Robotics Ltd.

Arbe (NASDAQ: ARBE), a global leader in ultra-high-resolution radar solutions, is redefining radar as a core sensing platform for next-generation mobility and defense. Arbe’s complete radar technology stack, from proprietary chipsets to radar systems and AI algorithms that produce perception-ready data, delivers the detail and real-time processing that demanding sensing applications require. Arbe enables OEMs, Tier-1s, and defense integrators to build more capable perception systems for passenger vehicles, robotaxis, heavy machinery, and counter-drone systems.

Headquartered in Tel Aviv, Israel, Arbe also operates offices in the United States, Germany, and China. For more information, visit https://arberobotics.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the intended use of net proceeds from the offering. The words “expect,” “believe,” “estimate,” “intend,” “plan,” “anticipate,” “may,” “should,” “strategy,” “future,” “will,” “project,” “potential” and similar expressions indicate forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These risks and uncertainties include the possible delisting of the Company’s ordinary shares from Nasdaq in the event the bid price per share of the Company’s ordinary shares remains below $1.00, the effect on the Israeli economy generally and on the Company’s business resulting from the terrorism and the hostilities in Israel, including the continuing hostilities with Iran, Hezbollah, and Hamas and any intensification of hostilities, and the effect of the call-up of a significant portion of its working population, including the Company’s employees, the ability of the Company to develop and market the Alerion radar system and deliver units in a timely and profitable manner, the ability of the Alerion radar system to operate as planned under wartime conditions, and the risks and uncertainties described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the SEC on March 27, 2026, as well as other documents filed by the Company with the SEC. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation. Information contained on, or that can be accessed through, the Company’s website or any other website or any social media is expressly not incorporated by reference into and is not a part of this press release.

Investor Relations:

Ehud Helft & Kenny Green
EK Global Investor Relations
investors@arberobotics.com
+1 212 378 8040

NEW YORK and HONG KONG, Sept. 28, 2026 (GLOBE NEWSWIRE) — Futurewave Acquisition Corporation (Nasdaq: FWAC) (“Futurewave”), a Cayman Islands special purpose acquisition company, and Olympian Group Inc., a Cayman Islands exempted company (“Olympian”) today announced that they have entered into a definitive Agreement and Plan of Merger dated September 28, 2026 (the “Merger Agreement”). Olympian is a solutions provider through its wholly owned Hong Kong subsidiary, HK Shang Ge Industrial Limited, specializing in integrated chip and electronic component solutions, including product solutions and value-added services in Hong Kong. Upon consummation of the transactions contemplated by the Merger Agreement, the combined company is expected to be Nasdaq-listed. The proposed transactions contemplated by the Merger Agreement are subject to customary closing conditions, including regulatory and shareholder approvals.

Integrated Chip and Electronic Component Solutions in Hong Kong

Olympian Group Inc. is a Cayman Islands exempted company and a holding company of HK Shang Ge Industrial Limited, a private company incorporated and existing under the laws of Hong Kong. Through HK Shang Ge Industrial Limited, Olympian is a solutions provider specializing in integrated chip and electronic component solutions. The Company operates within the Automotive Electronics & Industrial Connectivity sectors, integrating upstream semiconductor and electronic component resources with downstream application and product requirements. Its vertically oriented business model is focused on developing and delivering integrated electronic component solutions tailored to specific application scenarios, encompassing component selection, specification alignment, and supply-chain integration. Through this model, Olympian is positioned across key segments of the automotive electronics and industrial connectivity value chains, supporting the evolving requirements of intelligent vehicles, connected industrial systems, and other technology-driven applications.

Management Comments

“Our business is built around more than moving chips and electronic components from one point to another. Customers need a partner that can organize a vertical supply chain, match the right product solution to their application, and fulfill that requirement with speed and reliability. This proposed combination is intended to provide Olympian with a listed platform and additional resources to deepen those fulfillment capabilities and expand the solutions we deliver,” said Ms. Hantao Cui, Chief Executive Officer of Olympian Group Inc.

“Futurewave set out to identify a business with a clear operating focus, a defensible market position, and a management team oriented toward long-term customer relationships. We believe Olympian’s solutions model, centered on a vertically oriented supply chain, meets that brief. We look forward to working with Olympian’s team to complete the proposed transactions and to supporting the combined company as a Nasdaq-listed platform,” said Daniel M. McCabe, Chief Executive Officer of Futurewave.

Transaction Overview

Under the terms of the Merger Agreement, (i) Futurewave will merge with and into Olympian Global Inc., a Cayman Islands exempted company and wholly owned subsidiary of Futurewave (“Purchaser”), with Purchaser surviving the merger (the “Reincorporation Merger”), and (ii) concurrently with the Reincorporation Merger, FWAC Merger Sub Ltd., a Cayman Islands exempted company and wholly owned subsidiary of Purchaser (“Merger Sub”), will merge with and into Olympian, with Olympian surviving as a wholly owned subsidiary of Purchaser (the “Acquisition Merger”). Purchaser after the Reincorporation Merger is referred to as “PubCo.”

At the effective time of the Reincorporation Merger, (i) each issued and outstanding unit of Futurewave will automatically separate into one Futurewave ordinary share, one Futurewave warrant and one Futurewave right, (ii) each Futurewave ordinary share will be converted into one Purchaser Class A ordinary share, (iii) each Futurewave warrant will be converted into one Purchaser warrant, and (iv) each Futurewave right will be converted into one Purchaser right. At the closing of the transactions, each Purchaser right will be canceled in exchange for one-fourth (1/4) of one Purchaser Class A ordinary share, subject to the treatment of fractional shares set forth in the Merger Agreement.

Upon the closing of the Acquisition Merger, Olympian shareholders will receive an aggregate of 40,000,000 Purchaser ordinary shares, valued at $10.00 per share, based on a Company Net Value of $400,000,000. The Purchaser ordinary shares issued to Olympian’s key founders identified in the Merger Agreement will be Purchaser Class B ordinary shares, and all other shares issued to Olympian shareholders will be Purchaser Class A ordinary shares. Each Purchaser Class A ordinary share will carry one vote, and each Purchaser Class B ordinary share will carry ten votes and be convertible, at the holder’s option, into one Purchaser Class A ordinary share.

Following the Reincorporation Merger, the board of directors of PubCo will consist of five directors, including one independent director appointed by Futurewave and four directors appointed by Olympian, with at least a majority qualifying as independent directors under applicable securities laws and Nasdaq rules. The Merger Agreement also contemplates lock-up restrictions on the Purchaser ordinary shares issued to Olympian’s key founder shareholders until the earlier of six months after closing or the date on which the closing price of Purchaser Class A ordinary shares equals or exceeds $12.50 per share for 20 trading days within any 30-trading-day period, subject to customary permitted-transfer exceptions.

Additional information about the proposed transactions, including a copy of the Merger Agreement, will be provided in a Current Report on Form 8-K to be filed by Futurewave with the SEC and will be available at www.sec.gov.

ADVISORS

Celine and Partners, P.L.L.C. is acting as legal advisor to Futurewave. Loeb & Loeb LLP is acting as legal advisor to Olympian. Chain Stone Capital Limited (“CTM”) is acting as financial advisor to Olympian.

About Olympian Group Inc.

Olympian Group Inc. is a Cayman Islands exempted company and a holding company of HK Shang Ge Industrial Limited. Through its wholly owned Hong Kong subsidiary, Olympian is a solutions provider specializing in vertically oriented integrated chip and electronic component solutions, encompassing supply chain, product solutions and value-added services focused on customer fulfillment.

About Futurewave Acquisition Corporation

Futurewave Acquisition Corporation is a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. Futurewave’s units, ordinary shares, warrants and rights are listed on the Nasdaq Capital Market under the symbols FWACU, FWAC, FWACW and FWACR, respectively.

Additional Information and Where to Find It

The proposed transactions will be submitted to shareholders of Futurewave for their consideration and approval. In connection with the transaction described herein, Futurewave and Olympian intend to jointly file with the SEC a registration statement on Form F-4 (as may be amended from time to time) that will include a proxy statement/prospectus (the “Registration Statement”) pertaining to such transaction. After the Registration Statement is filed and declared effective, a definitive proxy statement and a proxy card will be mailed to Futurewave’s shareholders as of a record date to be established for voting at the shareholders’ meeting relating to the proposed transactions. Futurewave’s shareholders will also be able to obtain a copy of the Registration Statement and proxy statement without charge from Futurewave. The Registration Statement and proxy statement, once available, may also be obtained without charge at the SEC’s website at www.sec.gov or by writing to Futurewave at 1185 Avenue of the Americas, Suite 349, New York, NY 10036.

INVESTORS AND SECURITY HOLDERS OF FUTUREWAVE ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTIONS THAT FUTUREWAVE AND OLYMPIAN WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT FUTUREWAVE, OLYMPIAN AND THE TRANSACTIONS.

Participants in the Solicitation

Futurewave, Purchaser, Merger Sub, the Company, certain shareholders of the Company, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the Futurewave’s shareholders in respect of the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Futurewave’s shareholders in connection with the proposed transactions will be set forth in the proxy statement/prospectus to be filed with the SEC in connection with the transactions. You can find more information about Futurewave’s directors and executive officers and their ownership of Futurewave’s securities in Futurewave’s initial public offering prospectus dated June 25, 2026, filed with the SEC on June 26, 2026, as modified or supplemented by other reports filed with the SEC. Additional information regarding the interests of the participants in the proxy solicitation will be included in the proxy statement/prospectus pertaining to the proposed transaction when it becomes available. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. These documents can be obtained free of charge from the sources indicated above.

No Offer or Solicitation

This report shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of any business combination. This report shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” including, among other things, statements regarding the anticipated benefits and impact of the proposed transactions on PubCo’s business and future financial and operating results, the anticipated timing of closing of the proposed transactions, the anticipated growth of the industries and markets in which Olympian competes, the success and customer acceptance of Olympian’s product solutions and value-added services, and other aspects of Olympian’s operations, plans, objectives, opportunities, expectations or operating results, the expected ownership structure of PubCo and the likelihood and ability of the parties to successfully consummate the proposed transactions. Words such as “may,” “should,” “will,” “believe,” “expect,” “anticipate,” “intend,” “estimated,” “target,” “project,” and similar phrases or words of similar meaning that denote future expectations or intent regarding Futurewave’s, Olympian’s and PubCo’s financial results, operations and other matters are intended to identify forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Such forward-looking statements are based upon the current beliefs and expectations of management of Futurewave and Olympian and are inherently subject to significant business, economic and competitive risks, uncertainties and other factors, both known and unknown, which are difficult to predict and generally beyond the control of Futurewave and Olympian and that may cause actual results and the timing of future events to differ materially from the results and timing of future events anticipated by the forward-looking statements in this press release, including but not limited to: (1) the inability of Olympian and Futurewave to consummate an initial business combination within the time provided in Futurewave’s amended and restated memorandum and articles of association; (2) performance of Olympian’s business; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (4) the outcome of any potential litigation, government and regulatory proceedings, any investigations and inquiries involving the parties to the transactions; (5) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Futurewave or other conditions to closing in the Merger Agreement; (6) delays in obtaining or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Merger Agreement; (7) the inability to obtain or maintain the listing of the post-acquisition company’s securities on Nasdaq following the business combination; (8) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (9) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (10) costs related to the business combination; (11) changes in applicable laws or regulations; (12) the possibility that Olympian or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (13) other risks and uncertainties to be identified in the Registration Statement to be jointly filed by Futurewave and Olympian relating to the business combination, including those under “Risk Factors” therein, and in other filings with the SEC made by FWAC and Purchaser. The forward-looking statements contained in this press release are also subject to additional risks, uncertainties and factors, including those described in Futurewave’s IPO prospectus dated June 25, 2026 and other documents filed or to be filed with the SEC by Futurewave and Olympian from time to time. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond the control of Futurewave or Olympian. The forward-looking statements included in this press release are made only as of the date hereof, and Futurewave and Olympian disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date hereof. Forecasts and estimates regarding Olympian’s industry and end markets are based on sources Futurewave and Olympian believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Annualized, pro forma, projected and estimated numbers are used for illustrative purposes only, are not forecasts and may not reflect actual results.

Contact Information:

Futurewave Acquisition Corporation
Daniel M. McCabe
Email: admin@futurewaveacq.com 

Olympian Group Inc.
Hantao Cui
Email: christinacui@mtxpack.com 

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone

SANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the iFuse Granite Onyx System (Onyx). This is SI-BONE’s first product addressing the problem of compromised bone which is intended for use outside the pelvis, expanding the market opportunity for the company’s 3D-printed bone integration platform.

SI-BONE is redefining spinal fusion with Onyx, an innovation designed to address loosening at the upper and lower instrumented vertebrae (UIV and LIV, respectively) of a spinal fusion construct. Loosening occurs in the UIV and LIV in as many as 27% of fusion constructs.^1,2 The loosening risk is elevated for patients with low bone density, contributing to higher revision rates and cost of care.^1,3 Onyx was designed to address this issue in fusion procedures with the needs of patients with poor bone quality in mind.

Onyx doesn’t just iterate on existing designs. It reimagines them. The technology is built on a bone-density-specific surface and anatomy-specific thread form. Onyx is designed to allow for rapid osseointegration and to reduce micromotion, with the goal of early fixation and reduced screw loosening as a result of the osseointegration.

“Loss of fixation due to screw loosening in spinal fusions at the UIV and LIV is an unmet clinical need that has driven the search for a better solution,” said Han Jo Kim, M.D., Professor and David B. Levine, M.D. Endowed Chair in Spine Surgery at the Hospital for Special Surgery (HSS). “The Onyx system gives surgeons the opportunity to face our understanding of construct loosening with a novel innovation that translates into a meaningful step forward for our patients.”

“Patients with poor bone quality have historically had limited options in spinal fixation, and they are the least able to tolerate a second operation should the fixation fail,” said Gregory M. Mundis, Jr., M.D., Professor of Orthopedic Spine Surgery at Scripps Clinic and President of the San Diego Spine Foundation. “Onyx is designed around the mechanical realities of poor-quality bone, with a form factor intended to achieve early fixation where conventional technologies struggle. Having an option built for this population is a meaningful step for the patients who need it most.”

“Onyx is our third platform designated as a breakthrough device that is addressing a known large unmet need in fusion procedures. Our team built this proprietary technology for the patients who historically have been the hardest to treat,” said Laura Francis, Chief Executive Officer at SI-BONE. “iFuse Bedrock Granite®, our first breakthrough designated device, proved what osseointegrative technology can do at the base of a multi-level construct. Onyx applies those same principles to spinal fusion and is the most technologically advanced system we have ever brought to market. We believe Onyx will allow us to provide additional products to the surgeons already using Granite and also expand our reach to a broader group of surgeons who will want to incorporate this technology in their spinal fusion procedures.”

References:

1. Arena JD, et al. J Neurosurg Spine. 2024.
2. Odland K, et al. Int J Spine Surg. 2025.
3. Yuan, et al. Global Spine J. 2023.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the addressable market for iFuse Granite Onyx, its anticipated clinical and technical performance, and its expected commercialization. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the company’s filings with the Securities and Exchange Commission. SI-BONE undertakes no obligation to update any forward-looking statement.

About SI-BONE, Inc.

SI-BONE (Nasdaq: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 190 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

iFuse Granite Onyx is a trademark of SI-BONE, Inc. iFuse Bedrock Granite and SI-BONE are registered trademarks of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.

Han Jo Kim, M.D. and Gregory Mundis, M.D. are paid consultants to SI-BONE, Inc. and have royalty interests in Onyx.

Investor Contact: Saqib Iqbal, investors@si-bone.com

Collaboration pairs Cibus’ platform for improving a plant’s own genes with Crystal Crop’s mustard varieties and its reach across India, with the goal of putting better-performing seed in growers’ hands in a fraction of the time of conventional breeding

SAN DIEGO and NEW DELHI, Sept. 28, 2026 (GLOBE NEWSWIRE) — Crystal Crop Protection Limited (“Crystal Crop”), an Indian crop solutions company, and Cibus, Inc. (Nasdaq: CBUS) a technology company that uses biology to produce sustainable ingredients and helps farmers grow more food with fewer inputs, today announced an agreement to develop gene-edited traits in Brassica juncea (“Mustard”). Mustard is the oilseed at the heart of Indian cooking, and India grows more of it than any other country, on roughly 8.5 million hectares (21 million acres). Even so, India imports more than half of the edible oil it consumes, roughly 17 million tonnes a year, most of it palm and soybean oil. A better-performing mustard crop could mean more income for the grower and more of India’s cooking oil grown at home.

Cibus helps make good crops better, changing the speed and scale of plant breeding. Its platform makes precise changes to a plant’s own genes, with no foreign DNA added, and can deliver improved varieties in a fraction of the time of conventional breeding. Under the agreement, Crystal Crop will collaborate with Cibus to develop gene-edited traits in Brassica juncea and evaluate and commercialize such traits under an exclusive license in India. Crystal Crop brings its mustard production program, its knowledge of India’s seed market, and a network of more than 14,823 independent distribution partners across 23 states and four union territories across India, as of March 31, 2026, so improved seed can reach farmers at scale.

“Mustard matters to India the way few crops matter to any country. Improving it has real consequences for farmers and for the country’s food supply,” said Peter Beetham, Ph.D., a plant scientist who co-founded Cibus and serves as its President and Chief Operating Officer. “We have spent 25 years learning how to make precise improvements to a plant’s own genes, and we do it in a fraction of the time and cost of conventional breeding. Crystal Crop knows the Indian farmer and the Indian mustard market. Together we can put better seed in growers’ hands.”

The work answers a stated national priority. India’s National Mission on Edible Oils – Oilseeds, launched in 2024, aims to raise the country’s oilseed harvest from about 39 million tonnes (in 2022-23) to roughly 70 million tonnes by 2030-31 and names genome editing among the technologies it will use to get there. Indian mustard yields average 1,200 to 1,400 kilograms per hectare, against 1,800 to 2,000 in the leading producing countries, and breeders have struggled for decades to close that gap with conventional methods.

India has also drawn the line that gives this work a clear path to the field. In 2022, India’s environment ministry determined that crops improved through edits to their own genes, with no foreign DNA introduced, fall outside its rules for genetically modified organisms.

“Crystal Crop is customized for Indian farmers through research and development including by collaborations with various multi-national companies, delivering relevant solutions that aim to enhance farm economics, yield, productivity and profitability,” said Ankur Aggarwal, Chairman and Managing Director of Crystal Crop. “Pairing our mustard variety and our reach across India with Cibus’ platform technologies, we strive to offer growers a mustard that returns more from every acre. This is supposed to be a practical gain for farmers and for India’s oilseed economy.”

This agreement extends Cibus’ work in India and demonstrates how Cibus partners with regional seed and crop companies to bring improved crops to the farmers who need them.

About Cibus

Cibus (Nasdaq: CBUS) is a technology company that helps farmers grow more food with fewer inputs. Using its proprietary platform, Cibus improves a seed company’s best crop varieties by making precise changes to the plant’s own genes, with no foreign DNA added, then licenses those improvements back to the customer in exchange for royalties. Cibus is not a seed company. It develops crop traits at a fraction of the time and cost of conventional breeding, with a focus on higher yields, better quality, and reduced chemical use. For more information, visit www.Cibus.com.

About Crystal Crop Protection Limited

Crystal Crop Protection Limited, incorporated in 1994, is an Indian crop solutions company with agrochemicals and seeds at the core of its offerings. It operates on a fully integrated model, that integrates robust synthesis research and development in crop protection products and natural crop solutions as well as robust seeds breeding program, with backward-integrated technology enabled manufacturing and pan-India distribution, with a farmer-centric approach. In May 2026, Crystal Crop entered into agreements for the proposed acquisition of FMC Corporation’s India crop protection business i.e. FMC India Private Limited. For more information, visit www.crystalcropprotection.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding Cibus’ operational and financial performance, Cibus’ market opportunities, Cibus’ liquidity and capital resources, the implementation and execution of cost savings initiatives, Cibus’ strategy, future operations, prospects, and plans, including the anticipated integration into partner pipelines, implementation of commercial agreements, receipt of commercial revenues and additional funding and the achievement of commercial milestone targets, are forward-looking statements. Cibus’ assessment of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement. Because this involves such risks and uncertainties, the Company could use its available capital resources sooner than it currently expects. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend,” “expect,” “plan,” “scheduled,” “could,” “would” and “will,” or the negative of these and similar expressions.

These forward-looking statements are based on the current expectations and assumptions of Cibus’ management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. Cibus’ actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: Cibus’ need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; changes in expected or existing competition; challenges to Cibus’ intellectual property protection and unexpected costs associated with defending intellectual property rights; increased or unanticipated time and resources required for Cibus’ platform or trait product development efforts; Cibus’ reliance on third parties in connection with its development activities, including reliance on partner-funding and/or support for the advancement of its Sustainable Ingredients program; challenges associated with Cibus’ ability to effectively license its productivity traits and sustainable ingredient products; the risk that farmers do not recognize the value in germplasm containing Cibus’ traits or that farmers and processors fail to work effectively with crops containing Cibus’ traits; delays or disruptions in the Company’s platform or trait product development efforts, particularly insofar as they affect the Company’s strategic priority programs; challenges that arise in respect of Cibus’ production of high-quality plants and seeds cost effectively on a large scale; Cibus’ dependence on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses; regulatory developments that disfavor or impose significant burdens on gene editing processes or products; Cibus’ ability to achieve commercial success or to effectively negotiate commercial agreements; commodity prices and other market risks facing the agricultural sector; technological developments that could render Cibus’ technologies obsolete; changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates; dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on Cibus’ ability to execute on its business plan; the Company’s assessment of the period of time through which its financial resources will be adequate to support operations; and other important factors discussed in the “Risk Factors” section of Cibus’ Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2026, as may be updated from time-to-time in Cibus’ subsequently filed Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements.

In addition, the forward-looking statements included in this press release represent Cibus’ views as of the date hereof. Cibus specifically disclaims any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus’ views as of any date subsequent to the date hereof.

CRYSTAL CROP PROTECTION LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the draft red herring prospectus dated December 17, 2025 (“DRHP”) with SEBI and the Stock Exchanges. The DRHP is available on the website of SEBI at www.sebi.gov.in, on the websites of the Stock Exchanges i.e., BSE at www.bseindia.com, NSE at www.nseindia.com, on the websites of the BRLMs, i.e. IIFL Capital Services Limited (formerly known as IIFL Securities Limited) at www.iiflcapital.com, DAM Capital Advisors Limited at www.damcapital.in and Motilal Oswal Investment Advisors Limited at www.motilaloswal.com and the website of our Company at www.crystalcropprotection.com, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the section titled “Risk Factors” on page 41 of the DRHP and the details set out in the red herring prospectus (“RHP”), when filed. Potential investors should not rely on the DRHP for making any investment decision and should rely on the RHP, when filed, for making an investment decision.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction, including India. This announcement has been prepared for publication in India only and is not for publication or distribution, directly or indirectly, in or into the United States. The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933 (“U.S. Securities Act”) or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in ‘offshore transactions’ as defined in, and in reliance on Regulation S, and the applicable laws of the jurisdictions where such offers and sales are made. There will be no public offering of the Equity Shares in the United States.

CIBUS CONTACTS

Investor Relations:
Jeff Sonnek, jeff.sonnek@icrinc.com

Media Relations:
Colin Sanford, colin@bioscribe.com, 203-918-4347

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.

Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic dermatitis (AD) or with chronic pruritus. The ATTO-2306 poster will feature new preclinical data.

The EADV Congress 2026 will take place September 30 – October 3, 2026 in Vienna, Austria and FCD 2026 will take place on October 8-11, 2026 in Las Vegas, Nevada. Presentation details are below.

ATTO-1310

• EADV 2026 Poster Presentations
  • Title: Safety, Pharmacokinetics, and Pharmacodynamics of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein, in Healthy Adults (Abstract: AS-1248)
  • Title: Ultra-Sensitive Detection of Circulating IL-31 Reveals Elevated Levels Across Pruritic Skin Diseases (Abstract: AS-3150)
• FCD 2026 Poster Presentation
  • Title: Efficacy and Safety of a Single Dose of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein: Interim Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients with Atopic Dermatitis or with Chronic Pruritus

ATTO-2306

• FCD 2026 Poster Presentation
  • Title: Preclinical Characterization of ATTO-2306, a Long-Acting Bispecific Antibody Targeting IL-13 and IL-31 for Type 2 Inflammatory Skin Diseases

Following each congress, the posters will be available on the Publications page of the Attovia website at https://www.attovia.com.

About Attovia Therapeutics, Inc.
Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY™ biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.

Attovia’s lead programs include ATTO-1310, an anti-IL-31 ATTOBODY-based therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.

Investor and Media Contact

Attovia Therapeutics
ir@attovia.com

PJ Kelleher
LifeSci Advisors LLC
617-430-7579
pkelleher@lifesciadvisors.com